Peptide library / Digestive & weight / Amycretin
Amycretin
An investigational single molecule from Novo Nordisk that activates both GLP-1 and amylin receptors.
Effects studied or claimed
What it is used or promoted for, and where each effect has actually been seen
- Weight loss in obesitySmall human studies
- Type 2 diabetesSmall human studies
How it is thought to work
Amycretin combines the appetite and blood sugar effects of GLP-1 with the fullness signal of amylin in one peptide, given by injection or as a tablet.
What the evidence shows
An early trial of the weekly injection reported weight loss of about 22 percent at 36 weeks at the highest dose. Phase 3 trials have started.
Safety and unknowns
Gastrointestinal effects were the most common, as with other incretin drugs.
Regulatory status
Not approved. Phase 3 development is under way.
Regulatory status changes quickly. This entry was last reviewed on 27 October 2026. Confirm current status with the FDA before relying on it.
More in Digestive & weight
AOD-9604
Wellness and performanceA modified fragment of human growth hormone promoted for fat loss that did not work in large trials.
Apraglutide
In clinical trialsAn investigational weekly GLP-2 analog for short bowel syndrome with intestinal failure.
Albiglutide
FDA-approvedA weekly GLP-1 receptor agonist that proved heart benefit but was withdrawn for business reasons.
General information, not medical advice. Do not buy or inject unregulated peptides.